Turning high-throughput structural biology into predictive inhibitor design

Turning high-throughput structural biology into predictive inhibitor design

A common challenge in drug design pertains to finding chemical modifications to a ligand that increases its affinity to the target protein. An underutilized advance is the increase in structural biology throughput, which has progressed from an artisanal endeavor to a monthly throughput of hundreds o...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Saar, KL, McCorkindale, W, Fearon, D, Boby, M, Barr, H, Ben-Shmuel, A, London, N, von Delft, F, Chodera, JD, Lee, AA, Koekemoer, L, Krojer, T, Fairhead, M, MacLean, EM, Thompson, A, Smilova, MD, Wright, N, von Delft, A, Gileadi, C, Schofield, CJ, Salah, E, Malla, TR, Tumber, A, John, T, Vakonakis, I, Kantsadi, AL, Zitzmann, N, Brun, J, Kiappes, JL, Hill, M, Witt, KD, Alonzi, DS, Makower, LL, Giroud, C, Bennett, J, Fedorov, O, Morris, GM, Ferla, M, Carbery, A, Cattermole, E, Taylor, JC, Brewitz, L
Andere auteurs: COVID Moonshot Consortium
Formaat: Journal article
Taal:English
Gepubliceerd in: National Academy of Sciences 2023

Gelijkaardige items

Gelijkaardige items